Johnson & Johnson announced on February 18th a more than $1 billion investment in a next generation cell therapy manufacturing facility on a 154-acre property at 1201 Sumneytown Pike in Spring House (Lower Gwynedd). According to the announcement, “This new facility will further expand the Company’s U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases.”
“For 140 years, Johnson & Johnson has been a leading innovator in American healthcare, and we are honored to continue advancing that legacy in Pennsylvania,” said Joaquin Duato, chairman and chief executive officer of Johnson & Johnson. “By uniting scientific excellence with state-of-the-art manufacturing and strategic investment, and by working collaboratively with our communities, we are delivering for patients and creating significant opportunities for workers and families.”
According to Johnson and Johnson, the facility is expected to create 4,000 jobs during the construction phase and 500 skilled biomanufacturing jobs once open. Johnson & Johnson is no stranger to Spring House, it has an existing facility in the community that employs 2,500 people.
“Pennsylvania is a powerhouse for innovation and manufacturing in the life sciences,” said Governor Josh Shapiro. “Just a few years ago we weren’t even on the field – but today we’re competing and winning. We’ve done it by creating the first economic development plan for Pennsylvania in 2 decades, and following through on it by cutting red tape, making strategic investments in key industries like the life sciences, and strengthening our workforce. That’s why companies like Johnson & Johnson are choosing to double down on their investments here in our Commonwealth – because they know we’ve got the strategy, the workforce, and the speed they need to succeed.”
What Pennsylvania’s politicians are saying:
“Pennsylvania leads in life sciences and advanced manufacturing because we consistently deliver what companies like Johnson & Johnson need to succeed: a skilled workforce, premier research institutions, and proven manufacturing strength,” said U.S. Senator Dave McCormick. “This $1 billion-plus investment in a new Lower Gwynedd facility is a testament to that leadership and will produce life-changing treatments for patients, along with new and good jobs for our Commonwealth.”
“Pennsylvania is a leader in health care innovation with some of the very best health care workers. Proud to see this more than $1 billion investment into Montgomery County and our Commonwealth,” said U.S. Senator John Fetterman. “Bringing new jobs, advanced manufacturing, and life-saving medicine to and for our communities is always something to celebrate.”
“Our region is home to world-class healthcare, science and research — and the opening of Johnson & Johnson’s cell therapy manufacturing facility in Lower Gwynedd expands its long tradition of leadership in Pennsylvania,” Representative Madeleine Dean said. “J&J’s new site will promote job growth, foster innovation, and, most importantly, bring life-saving medicine to people around the country. I look forward to their continued success.”
Image: Johnson & Johnson
